Early Intervention with IntelligynAI

An innovative clinical decision support tool designed to enhance ovarian cancer diagnosis accuracy.

Why IntelligynAI?

The Urgency of Early Detection

Ovarian cancer is a silent killer, often detected too late. It's the fifth leading cause of cancer-related death among women, claiming countless lives every year.

It often goes undetected until it has spread within the pelvis and abdomen. While it can occur at any age, it is most common in women after menopause. Early detection is crucial for successful treatment, which typically involves surgery and chemotherapy.

Get accurate ovarian tumor analysis in seconds

IntelligynAI is a software platform that uses artificial intelligence to analyze ultrasound images and assess the risk of ovarian cancer.  

It's designed to be used by healthcare professionals during routine gynecological exams and integrated with existing workflow.

How IntelligynAI works?

Step 1

Getting Started with Images

The process begins in the examiner’s office.

During a standard transvaginal ultrasound, the clinician selects images of the tumor and saves them on the ultrasound machine.

Step 2

Sending the Images

The ultrasound system's image menu allows the clinician to send these images directly to IntelligynAI for analysis. We recommend sending 3 images (greyscale and color Doppler) to capture tumor characteristics.

Step 3

Analyze the Results

Within seconds, our cloud-based platform processes the images and generates a comprehensive report with a risk prediction and patient management proposal. This report is sent back to the ultrasound system as a DICOM image, which the examiner can conveniently review directly on the ultrasound system or their workstation.

IntelligynAI analyzes the images using neural network models developed and validated on thousands of cases, to provide a risk score and management proposal

These results can also be accessed through the IntelligynAI application on any computer within your network.

Step 4

Tumor Status

The analysis results in one of three possible statuses: benign tumor, malignant tumor, or inconclusive.

IntelligynAI can identify 93.7% of benign tumors and 97.1% of malignant tumors with an accuracy superior to human examiners. In the remaining cases, classification as benign or malignant is not possible. This may occur when the tumor is not visible or when a high degree of uncertainty exists.

IntelligynAI provides doctors and patients with time-saving and reliable diagnoses, reducing the need for unnecessary referrals or surgeries, as well as delayed cancer diagnosis

Data Security & Compliance

IntelligynAI is committed to ensuring the highest levels of data security and compliance with industry standards. Our system operates within an air-gapped environment at the hospital, keeping the ultrasound system disconnected from the hospital's general network. This secure setup maintains the privacy and integrity of patient data while facilitating seamless communication between the ultrasound system and IntelligynAI.  

Our platform is designed to comply with relevant healthcare data regulations, including GDPR and HIPAA, ensuring that patient information is managed responsibly and securely.

We prioritize adherence to industry standards, guaranteeing that our cutting-edge technology integrates seamlessly with existing healthcare infrastructure.

Technology & Integration

IntelligynAI is compatible with all ultrasound manufacturers using DICOM, DICOM SR, and DICOM WL. Setting up IntelligynAI is quick and straightforward. The ultrasound system is configured to add a DICOM endpoint, which creates a secure connection with IntelligynAI for streamlined data transfer during the diagnostic process. This ensures seamless integration with your existing ultrasound equipment and workflows.

Request a Demo

Contact us!

Let’s work together to improve patient outcomes and streamline your diagnostic process.

FAQs

  • IntelligynAI is a cutting-edge platform that provides real-time diagnostic support for examiners evaluating ovarian tumors. It uses advanced AI-algorithms and cloud-based technology to analyze ultrasound images and generate a risk prediction for ovarian cancer, along with a personalized patient management proposal.

  • IntelligynAI has demonstrated high accuracy in predicting ovarian cancer risk, based on clinical studies and ongoing research. The platforms performance continues to improve as we gather more data and refine our algorithms.

  • Absolutely. We take data security and privacy seriously and comply with industry standards such as GDPR and HIPAA. IntelligynAI operates within an air-gapped environment, ensuring that patient data remains protected while enabling seamless communication with ultrasound systems.

  • IntelligynAI supports healthcare providers by improving diagnostic accuracy and efficiency, reducing variability in diagnoses due to differences in examiner experience. For patients, this means more reliable diagnoses, personalized treatment plans, and potentially fewer unnecessary surgeries, leading to better health outcomes.

  • We welcome participation from healthcare providers worldwide in our ongoing clinical studies and research efforts. If you are interested in contributing to the development and improvement of IntelligynAI, please reach out to us at admin@intelligyn.ai. Your participation will help us continue to advance our platform and improve women’s healthcare worldwide.